Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.
Company Growth (employees)
Key People at Five Prime Therapeutics
Aron Knickerbocker
Marc Belsky
Five Prime Therapeutics Office Locations
Five Prime Therapeutics Data and Metrics
Five Prime Therapeutics Financial Metrics
Net income (Q1, 2017) | (33.4 b) |
EBIT (Q1, 2017) | (34.1 b) |
Market capitalization (17-Aug-2017) | 796.5 m |
Cash (31-Dec-2016) | 7.7 m |
| USD | FY, 2013 | FY, 2016 |
|---|---|---|
R&D expense | 94.1 b | |
General and administrative expense | 35.8 b | |
Operating expense total | 43.2 m | 129.9 b |
EBIT | (29.4 m) | (99.2 b) |
Interest income | 2.5 b | |
Pre tax profit | (96.7 b) | |
Income tax expense | 31 b | |
Net Income | (28.9 m) | (65.7 b) |
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|
R&D expense | 13.3 m | 24.7 m | 18.3 b | 22.2 b | 23.9 b | 33.8 b |
General and administrative expense | 4.6 m | 5.2 m | 8.6 b | 8.1 b | 9.1 b | 10.5 b |
Operating expense total | 17.9 m | 29.9 m | 26.9 b | 30.3 b | 33 b | 44.2 b |
EBIT | (11.6 m) | (24.1 m) | (20.4 b) | (21.1 b) | (26.4 b) | (34.1 b) |
Interest income | 117 k | 107 k | 536 m | 646 m | 639 m | 668 m |
Pre tax profit | (19.9 b) | (20.4 b) | (25.7 b) | (33.4 b) | ||
Income tax expense | 6.8 b | 7.3 b | 6.3 b | |||
Net Income | (11.5 m) | (24 m) | (13 b) | (13.1 b) | (19.4 b) | (33.4 b) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 8.2 m | 15.3 m | 150 m | 7.7 m |
Current Assets | 77.7 m | 151.3 m | 528.3 m | 440.1 m |
PP&E | 3.7 m | 3.8 m | 4.5 m | 6.2 m |
Total Assets | 81.8 m | 155.6 m | 548.3 m | 448.3 m |
Accounts Payable | 348 k | 1.1 m | 1.9 m | 334 k |
Current Liabilities | 13.8 m | 19.8 m | 79.4 m | 38.7 m |
Common Stock | 17 k | |||
Additional Paid-in Capital | 209.6 m | 274.2 m | 372.6 m | 396.6 m |
Retained Earnings | (151.6 m) | (189 m) | 60.6 m | (5 m) |
Total Equity | 58 m | 433.2 m | 391.6 m | |
Financial Leverage | 1.4 x | 1.3 x | 1.1 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (28.9 m) | (37.4 m) | 249.6 m | (65.7 m) |
Depreciation and Amortization | 1.7 m | 1.6 m | 1.7 m | 1.7 m |
Accounts Payable | (209 k) | 701 k | 798 k | (1.6 m) |
Cash From Operating Activities | (25.3 m) | 15.3 m | 289.1 m | (79.8 m) |
Purchases of PP&E | (807 k) | (1.6 m) | (2.4 m) | (3 m) |
Cash From Investing Activities | (42.2 m) | (69.4 m) | (238.2 m) | (53.7 m) |
Cash From Financing Activities | 64.3 m | 61.2 m | 83.8 m | (8.9 m) |
Income Taxes Paid | 11.4 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (11.5 m) | (24 m) | (13 b) | (13.1 b) | (19.4 b) | (33.4 b) | |||
Accounts Payable | 767 k | 672 k | 904 k | 1.4 m | 1.6 m | 1 m | 654 k | 528 k | 807 k |
